| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 41 | 2024 | 358 | 10.660 |
Why?
|
| Colitis, Ulcerative | 23 | 2024 | 260 | 6.540 |
Why?
|
| Crohn Disease | 23 | 2024 | 329 | 6.440 |
Why?
|
| Natural Language Processing | 7 | 2022 | 112 | 1.710 |
Why?
|
| Veterans | 10 | 2022 | 1742 | 1.670 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2018 | 453 | 1.500 |
Why?
|
| United States Department of Veterans Affairs | 11 | 2024 | 664 | 1.340 |
Why?
|
| Critical Pathways | 2 | 2019 | 160 | 1.100 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2024 | 18 | 1.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2023 | 1571 | 1.010 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2019 | 139 | 1.000 |
Why?
|
| Gastrointestinal Agents | 2 | 2017 | 119 | 0.980 |
Why?
|
| Gastroenterology | 5 | 2024 | 202 | 0.940 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 98 | 0.930 |
Why?
|
| Colitis | 2 | 2020 | 340 | 0.920 |
Why?
|
| Colonoscopy | 5 | 2022 | 524 | 0.870 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 355 | 0.870 |
Why?
|
| Quality Improvement | 4 | 2020 | 912 | 0.850 |
Why?
|
| Colorectal Neoplasms | 7 | 2022 | 3706 | 0.840 |
Why?
|
| United States | 31 | 2024 | 15834 | 0.820 |
Why?
|
| Biological Products | 3 | 2023 | 318 | 0.770 |
Why?
|
| Anxiety | 2 | 2020 | 1244 | 0.760 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 601 | 0.750 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 718 | 0.750 |
Why?
|
| Diet | 5 | 2019 | 1469 | 0.740 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 819 | 0.690 |
Why?
|
| Immunosuppressive Agents | 5 | 2022 | 1439 | 0.680 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2021 | 277 | 0.680 |
Why?
|
| Veterans Health | 5 | 2021 | 174 | 0.680 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2021 | 972 | 0.660 |
Why?
|
| Depression | 2 | 2020 | 1733 | 0.630 |
Why?
|
| Gastrointestinal Diseases | 2 | 2014 | 616 | 0.630 |
Why?
|
| Humans | 86 | 2024 | 270804 | 0.610 |
Why?
|
| Hematinics | 1 | 2019 | 108 | 0.600 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1042 | 0.590 |
Why?
|
| Age of Onset | 2 | 2016 | 853 | 0.580 |
Why?
|
| Gastric Acid | 1 | 2017 | 54 | 0.560 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 118 | 0.560 |
Why?
|
| Intestinal Mucosa | 6 | 2021 | 1112 | 0.560 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 57 | 0.550 |
Why?
|
| Virus Activation | 1 | 2018 | 241 | 0.530 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 225 | 0.530 |
Why?
|
| Tuberculin Test | 1 | 2017 | 136 | 0.530 |
Why?
|
| Middle Aged | 42 | 2024 | 90569 | 0.520 |
Why?
|
| Fissure in Ano | 1 | 2015 | 8 | 0.520 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 86 | 0.510 |
Why?
|
| Databases, Factual | 4 | 2018 | 2261 | 0.510 |
Why?
|
| Hepatitis B | 1 | 2018 | 273 | 0.500 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 121 | 0.500 |
Why?
|
| Proton Pump Inhibitors | 2 | 2018 | 272 | 0.490 |
Why?
|
| Male | 48 | 2024 | 128520 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 626 | 0.480 |
Why?
|
| Aged | 34 | 2024 | 73640 | 0.470 |
Why?
|
| Behavior Therapy | 1 | 2017 | 302 | 0.470 |
Why?
|
| Colon | 5 | 2021 | 684 | 0.460 |
Why?
|
| Gastroenterologists | 2 | 2024 | 21 | 0.460 |
Why?
|
| Cost of Illness | 1 | 2017 | 506 | 0.450 |
Why?
|
| Scedosporium | 1 | 2013 | 24 | 0.440 |
Why?
|
| Risk Factors | 17 | 2022 | 17867 | 0.440 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 637 | 0.430 |
Why?
|
| Stress, Psychological | 2 | 2017 | 1038 | 0.430 |
Why?
|
| Diet Therapy | 1 | 2013 | 52 | 0.430 |
Why?
|
| Safety-net Providers | 1 | 2013 | 55 | 0.430 |
Why?
|
| Female | 45 | 2024 | 148936 | 0.430 |
Why?
|
| Frontal Lobe | 1 | 2013 | 169 | 0.420 |
Why?
|
| Brain Abscess | 1 | 2013 | 74 | 0.410 |
Why?
|
| Adult | 34 | 2024 | 82073 | 0.410 |
Why?
|
| Infliximab | 3 | 2022 | 138 | 0.410 |
Why?
|
| Leukopenia | 1 | 2012 | 152 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 1225 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1416 | 0.400 |
Why?
|
| Disease Management | 2 | 2017 | 1092 | 0.390 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 1437 | 0.390 |
Why?
|
| Algorithms | 6 | 2022 | 3908 | 0.390 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 205 | 0.390 |
Why?
|
| Medical Audit | 1 | 2012 | 194 | 0.390 |
Why?
|
| Proctitis | 1 | 2011 | 19 | 0.380 |
Why?
|
| Health Personnel | 1 | 2017 | 650 | 0.370 |
Why?
|
| Lichen Planus, Oral | 1 | 2010 | 9 | 0.370 |
Why?
|
| Barrett Esophagus | 4 | 2022 | 560 | 0.370 |
Why?
|
| Digestive System Neoplasms | 1 | 2011 | 79 | 0.370 |
Why?
|
| Logistic Models | 6 | 2020 | 3430 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2022 | 9464 | 0.360 |
Why?
|
| Caregivers | 1 | 2017 | 759 | 0.360 |
Why?
|
| Prevalence | 5 | 2021 | 3395 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 563 | 0.340 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2010 | 68 | 0.340 |
Why?
|
| Endoscopy | 1 | 2013 | 495 | 0.340 |
Why?
|
| Androstadienes | 1 | 2010 | 172 | 0.340 |
Why?
|
| Mycoses | 1 | 2013 | 392 | 0.340 |
Why?
|
| Diarrhea | 1 | 2013 | 722 | 0.330 |
Why?
|
| Retrospective Studies | 18 | 2022 | 39982 | 0.320 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 402 | 0.320 |
Why?
|
| Cryosurgery | 1 | 2011 | 197 | 0.320 |
Why?
|
| Radiation Injuries | 2 | 2020 | 1476 | 0.310 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2020 | 379 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 2395 | 0.300 |
Why?
|
| Odds Ratio | 5 | 2020 | 2300 | 0.280 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 4495 | 0.280 |
Why?
|
| Young Adult | 12 | 2023 | 22255 | 0.270 |
Why?
|
| Program Evaluation | 3 | 2019 | 602 | 0.270 |
Why?
|
| Deglutition Disorders | 1 | 2010 | 487 | 0.270 |
Why?
|
| Immunologic Factors | 2 | 2023 | 669 | 0.260 |
Why?
|
| Quality of Life | 3 | 2022 | 4810 | 0.260 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4320 | 0.250 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2005 | 18 | 0.250 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2005 | 36 | 0.250 |
Why?
|
| Fetus | 1 | 2009 | 670 | 0.250 |
Why?
|
| Drug Prescriptions | 3 | 2024 | 309 | 0.250 |
Why?
|
| Stomach Ulcer | 1 | 2005 | 109 | 0.240 |
Why?
|
| Bacteria | 2 | 2019 | 650 | 0.240 |
Why?
|
| Hospitalization | 3 | 2021 | 2170 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 593 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 541 | 0.230 |
Why?
|
| Electronic Health Records | 3 | 2017 | 853 | 0.230 |
Why?
|
| Incidence | 5 | 2021 | 5824 | 0.230 |
Why?
|
| Postoperative Complications | 2 | 2021 | 5681 | 0.230 |
Why?
|
| Medical Marijuana | 1 | 2024 | 25 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 5779 | 0.220 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 2 | 2021 | 23 | 0.220 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1175 | 0.220 |
Why?
|
| Prednisone | 2 | 2021 | 1034 | 0.220 |
Why?
|
| Oxadiazoles | 1 | 2023 | 60 | 0.220 |
Why?
|
| Age Factors | 5 | 2019 | 5443 | 0.220 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 103 | 0.210 |
Why?
|
| Needs Assessment | 1 | 2024 | 235 | 0.210 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 165 | 0.200 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2022 | 5 | 0.200 |
Why?
|
| Erythema Nodosum | 1 | 2022 | 15 | 0.200 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 244 | 0.200 |
Why?
|
| Uveitis | 1 | 2022 | 40 | 0.200 |
Why?
|
| Endoscopy, Digestive System | 2 | 2014 | 211 | 0.200 |
Why?
|
| Treatment Outcome | 7 | 2019 | 33859 | 0.190 |
Why?
|
| Adolescent | 8 | 2023 | 32698 | 0.190 |
Why?
|
| Calbindin 2 | 1 | 2021 | 43 | 0.190 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2022 | 128 | 0.180 |
Why?
|
| Budesonide | 1 | 2021 | 35 | 0.180 |
Why?
|
| Chronic Disease | 3 | 2021 | 1825 | 0.180 |
Why?
|
| Tissue Adhesions | 1 | 2021 | 51 | 0.180 |
Why?
|
| Arthritis | 1 | 2022 | 148 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 850 | 0.180 |
Why?
|
| Metronidazole | 1 | 2021 | 170 | 0.180 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 5924 | 0.170 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 31117 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 1301 | 0.170 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 2348 | 0.170 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 15280 | 0.170 |
Why?
|
| Adult Stem Cells | 1 | 2020 | 73 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4966 | 0.160 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2018 | 2 | 0.160 |
Why?
|
| Abdomen | 1 | 2021 | 346 | 0.160 |
Why?
|
| Colitis, Microscopic | 1 | 2018 | 16 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4843 | 0.160 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 206 | 0.150 |
Why?
|
| Time Factors | 5 | 2021 | 12979 | 0.150 |
Why?
|
| Texas | 4 | 2019 | 6445 | 0.150 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 224 | 0.150 |
Why?
|
| Gelsolin | 1 | 2017 | 17 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2024 | 834 | 0.150 |
Why?
|
| Actin Cytoskeleton | 1 | 2017 | 77 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 359 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 574 | 0.140 |
Why?
|
| Methotrexate | 2 | 2012 | 1025 | 0.140 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 8 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2021 | 524 | 0.140 |
Why?
|
| Ileum | 1 | 2017 | 173 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2021 | 610 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2021 | 592 | 0.140 |
Why?
|
| Adalimumab | 1 | 2017 | 48 | 0.140 |
Why?
|
| Biological Therapy | 1 | 2017 | 57 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2021 | 614 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2019 | 480 | 0.140 |
Why?
|
| Data Mining | 1 | 2017 | 83 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 1061 | 0.140 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 89 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 155 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2021 | 697 | 0.130 |
Why?
|
| Mass Screening | 2 | 2017 | 1547 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 5157 | 0.130 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 106 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 417 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2005 | 1047 | 0.130 |
Why?
|
| Focus Groups | 1 | 2017 | 282 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 302 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 310 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 248 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2014 | 6766 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 226 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 490 | 0.120 |
Why?
|
| Blood Cells | 1 | 2015 | 127 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 4470 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2017 | 489 | 0.120 |
Why?
|
| Alopecia | 1 | 2015 | 125 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 705 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2017 | 437 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 4645 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 1467 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 387 | 0.110 |
Why?
|
| Pneumonia | 1 | 2020 | 792 | 0.110 |
Why?
|
| Saliva | 1 | 2015 | 233 | 0.110 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2013 | 19 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 1411 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 1329 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 509 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 441 | 0.110 |
Why?
|
| Adenoma | 2 | 2016 | 738 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 825 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2018 | 6234 | 0.110 |
Why?
|
| Colostomy | 1 | 2013 | 80 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 930 | 0.110 |
Why?
|
| Ileostomy | 1 | 2013 | 47 | 0.110 |
Why?
|
| Neoplasm Staging | 4 | 2022 | 14037 | 0.110 |
Why?
|
| Azathioprine | 1 | 2012 | 73 | 0.100 |
Why?
|
| Phenotype | 3 | 2024 | 6503 | 0.100 |
Why?
|
| Smoking | 2 | 2024 | 2549 | 0.100 |
Why?
|
| Mercaptopurine | 1 | 2012 | 130 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2015 | 228 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 1094 | 0.100 |
Why?
|
| United Kingdom | 2 | 2024 | 284 | 0.100 |
Why?
|
| Esophagus | 1 | 2015 | 562 | 0.100 |
Why?
|
| Stem Cells | 1 | 2018 | 1213 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1250 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 20 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2012 | 727 | 0.090 |
Why?
|
| Fluticasone | 1 | 2010 | 22 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 95 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 1345 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 2339 | 0.090 |
Why?
|
| Meat | 1 | 2011 | 91 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2017 | 1875 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 13422 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2017 | 1932 | 0.090 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2010 | 21 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2011 | 129 | 0.090 |
Why?
|
| Biopsy | 4 | 2020 | 3490 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 128 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2013 | 321 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 352 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 899 | 0.090 |
Why?
|
| Sex Factors | 1 | 2015 | 2180 | 0.090 |
Why?
|
| Biomarkers | 2 | 2019 | 5050 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 236 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2014 | 677 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 2011 | 247 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 173 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 1027 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 340 | 0.080 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 200 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 303 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 631 | 0.080 |
Why?
|
| Esophagoscopy | 1 | 2010 | 310 | 0.080 |
Why?
|
| Radiography | 1 | 2013 | 1998 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 297 | 0.080 |
Why?
|
| Vegetables | 1 | 2011 | 331 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1715 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 3190 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 924 | 0.080 |
Why?
|
| Recurrence | 1 | 2017 | 4878 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 626 | 0.080 |
Why?
|
| Protective Factors | 2 | 2021 | 103 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2022 | 571 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2009 | 248 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2022 | 542 | 0.070 |
Why?
|
| Prognosis | 3 | 2017 | 22533 | 0.070 |
Why?
|
| Pregnancy | 2 | 2010 | 7916 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 262 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4396 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 639 | 0.060 |
Why?
|
| Thalidomide | 1 | 2009 | 597 | 0.060 |
Why?
|
| Cause of Death | 2 | 2021 | 782 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 87 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2011 | 2855 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6193 | 0.060 |
Why?
|
| Fractures, Bone | 2 | 2016 | 310 | 0.050 |
Why?
|
| Indans | 1 | 2023 | 69 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 156 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 5870 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2010 | 1246 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2024 | 494 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 5099 | 0.050 |
Why?
|
| Remission Induction | 1 | 2009 | 3658 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 387 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 3241 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2015 | 2883 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7789 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 124 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7923 | 0.050 |
Why?
|
| Urologic Surgical Procedures | 1 | 2021 | 93 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 378 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 29 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 164 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2020 | 385 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2017 | 12036 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 28 | 0.040 |
Why?
|
| Actinomyces | 1 | 2018 | 5 | 0.040 |
Why?
|
| Actinobacteria | 1 | 2018 | 14 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 367 | 0.040 |
Why?
|
| Bacillus | 1 | 2018 | 39 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 184 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 715 | 0.040 |
Why?
|
| Alarmins | 1 | 2017 | 8 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1246 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 157 | 0.040 |
Why?
|
| Child | 1 | 2019 | 30572 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2017 | 90 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 852 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2021 | 381 | 0.040 |
Why?
|
| Clone Cells | 1 | 2018 | 589 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 604 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1113 | 0.040 |
Why?
|
| Receptors, CXCR6 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Sorting Nexins | 1 | 2016 | 17 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 23 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 7920 | 0.030 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2016 | 30 | 0.030 |
Why?
|
| Cell Separation | 1 | 2018 | 608 | 0.030 |
Why?
|
| Tenascin | 1 | 2016 | 50 | 0.030 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2016 | 35 | 0.030 |
Why?
|
| Adenylyl Cyclases | 1 | 2016 | 102 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 97 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 64 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2017 | 340 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 113 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 163 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2016 | 62 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 152 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8607 | 0.030 |
Why?
|
| Regional Medical Programs | 1 | 2015 | 20 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 233 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2018 | 699 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2015 | 78 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 115 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 618 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 685 | 0.030 |
Why?
|
| Software | 1 | 2022 | 1358 | 0.030 |
Why?
|
| Mesalamine | 1 | 2015 | 8 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 84 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 55 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 1683 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 164 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 396 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 369 | 0.030 |
Why?
|
| Leadership | 1 | 2016 | 271 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 1381 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2393 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2020 | 1005 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 501 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1295 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 3109 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 419 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1333 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 117 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2014 | 518 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 1308 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2212 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3058 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 378 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 6881 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2219 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 638 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 4905 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 866 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 2491 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 732 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9281 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 5692 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4102 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 2084 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1960 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7233 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 4839 | 0.020 |
Why?
|
| Pain | 1 | 2014 | 1701 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7323 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 61362 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4102 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 35420 | 0.010 |
Why?
|